Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model

Vaccine

Volumn 32, Issue 26, 2014, Pages 3264-3273

  Jones, Bart G ^a   Sealy, Robert E ^a   Surman, Sherri L ^a   Portner, Allen ^a   Russell, Charles J ^a,b   Slobod, Karen S ^c   Dormitzer, Philip R ^c   DeVincenzo, John ^b,d   Hurwitz, Julia L ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c Novartis Vaccines Cambridge   (United States)

^d LE BONHEUR CHILDREN'S MEDICAL CENTER   (United States)

Author keywords

Maternal antibody model; Neutralizing antibodies; Protective immunity; Respiratory syncytial virus vaccine; Sendai virus

Indexed keywords

HN PROTEIN; HUMAN IMMUNOGLOBULIN; MATERNAL ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; COTTON RAT; DRUG EFFICACY; EXPERIMENT; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; IN VIVO STUDY; INFANT; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SENDAI VIRUS; VACCINATION; VIRUS LOAD;

MATERNAL ANTIBODY MODEL; NEUTRALIZING ANTIBODIES; PROTECTIVE IMMUNITY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SENDAI VIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNIZATION, PASSIVE; INFANT; INFANT, NEWBORN; NEUTRALIZATION TESTS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; SENDAI VIRUS; SIGMODONTINAE;

EID: 84900441477     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.088     Document Type: Article

References (58)

1. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375:1545-1555.
2. Glezen W.P., Taber L.H., Frank A.L., Kasel J.A. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986, 140:543-546.
3. Shinoff J.J., O'Brien K.L., Thumar B., Shaw J.B., Reid R., Hua W., et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis 2008, 198:1007-1015.
4. Piedra P.A., Jewell A.M., Cron S.G., Atmar R.L., Glezen W.P. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 2003, 21:3479-3482.
5. Buckingham S.C., Quasney M.W., Bush A.J., DeVincenzo J.P. Respiratory syncytial virus infections in the pediatric intensive care unit: clinical characteristics and risk factors for adverse outcomes. Pediatr Crit Care Med 2001, 2:318-323.
6. Simoes E.A., Groothuis J.R., Carbonell-Estrany X., Rieger C.H., Mitchell I., Fredrick L.M., et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007, 151:34-42.
7. DeVincenzo J. Passive antibody prophylaxis for RSV. Pediatr Infect Dis J 2008, 27:69-70.
8. Boivin G., Caouette G., Frenette L., Carbonneau J., Ouakki M., De S.G. Human respiratory syncytial virus and other viral infections in infants receiving palivizumab. J Clin Virol 2008, 42:52-57.
9. Red book report of the committee on infectious diseases. American Academy of Pediatrics; 2009.
10. Collins P.L., Graham B.S. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 2008, 82:2040-2055.
11. Hurwitz J.L. Respiratory syncytial virus vaccine development. Expert Rev Vaccines 2011, 10:1415-1433.
12. Shaw C.A., Ciarlet M., Cooper B.W., Dionigi L., Keith P., O'Brien K.B., et al. The path to an RSV vaccine. Curr Opin Virol 2013, 3:332-342.
13. Lyn D., Gill D.S., Scroggs R.A., Portner A. The nucleoproteins of human parainfluenza virus type 1 and Sendai virus share amino acid sequences and antigenic and structural determinants. J Gen Vir 1991, 72:983-987.
14. Hurwitz J.L., Soike K.F., Sangster M.Y., Portner A., Sealy R.E., Dawson D.H., et al. Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one. Vaccine 1997, 15:533-540.
15. Zhan X., Hurwitz J.L., Krishnamurthy S., Takimoto T., Boyd K., Scroggs R.A., et al. Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B. Vaccine 2007, 25:8782-8793.
16. Jones B.G., Sealy R.E., Rudraraju R., Traina-Dorge V.L., Finneyfrock B., Cook A., et al. Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. Vaccine 2012, 30:959-968.
17. Jones B., Zhan X., Mishin V., Slobod K.S., Surman S., Russell C.J., et al. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. Vaccine 2009, 27:1848-1857.
18. Slobod K.S., Shenep J.L., Lujan-Zilbermann J., Allison K., Brown B., Scroggs R.A., et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 2004, 22:3182-3186.
19. Guilliams M., Bruhns P., Saeys Y., Hammad H., Lambrecht B.N. The function of Fcgamma receptors in dendritic cells and macrophages. Nat Rev Immunol 2014, 14:94-108.
20. Glezen W.P., Paredes A., Allison J.E., Taber L.H., Frank A.L. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981, 98:708-715.
21. Glezen W.P. Effect of maternal antibodies on the infant immune response. Vaccine 2003, 21:3389-3392.
22. Corthesy B., Kraehenbuhl J.P. Antibody-mediated protection of mucosal surfaces. Curr Top Microbiol Immunol 1999, 236:93-111.
23. Ravetch J.V., Clynes R.A. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol 1998, 16:421-432.
24. Sulica A., Morel P., Metes D., Herberman R.B. Ig-binding receptors on human NK cells as effector and regulatory surface molecules. Int Rev Immunol 2001, 20:371-414.
25. Stensballe L.G., Ravn H., Kristensen K., Meakins T., Aaby P., Simoes E.A. Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus. J Pediatr 2009, 154:296-298.
26. Groothuis J.R., Simoes E.A., Levin M.J., Hall C.B., Long C.E., Rodriguez W.J., et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993, 329:1524-1530.
27. Groothuis J.R., Hoopes J.M., Hemming V.G. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis. Adv Ther 2011, 28:110-125.
28. Rodriguez W.J., Gruber W.C., Groothuis J.R., Simoes E.A., Rosas A.J., Lepow M., et al. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics 1997, 100:937-942.
29. Groothuis J.R., Simoes E.A., Hemming V.G. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics 1995, 95:463-467.
30. Portner A. The HN glycoprotein of Sendai virus: analysis of site(s) involved in hemagglutinating and neuraminidase activities. Virology 1981, 115:375-384.
31. Prince G.A., Prieels J-P., Slaoui M., Porter D.D. Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus). Lab Invest 1999, 79:1385-1392.
32. Prince G.A., Jenson A.B., Hemming V.G., Murphy B.R., Walsh E.E., Horswood R.L., et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J Virol 1986, 57:721-728.
33. Prince G.A., Curtis S.J., Yim K.C., Porter D.D. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 2001, 82:2881-2888.
34. Anderson L.J., Hierholzer J.C., Bingham P.G., Stone Y.O. Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J Clin Microbiol 1985, 22:1050-1052.
35. Anderson L.J., Bingham P., Hierholzer J.C. Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J Virol 1988, 62:4232-4238.
36. Gorman W.L., Gill D.S., Scroggs R.A., Portner A. The hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus type 1 and sendai virus have high structure-function similarity with limited antigenic cross-reactivity. Virology 1990, 175:211-223.
37. Brandenburg A.H., Groen J., van Steensel-Moll H.A., Claas E.C., Rothbarth P.H., Neijens H.J., et al. Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J Med Virol 1997, 52:97-104.
38. Feltes T.F., Cabalka A.K., Meissner H.C., Piazza F.M., Carlin D.A., Top F.H., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003, 143:532-540.
39. Johnson S., Griego S.D., Pfarr D.S., Doyle M.L., Woods R., Carlin D., et al. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J Infect Dis 1999, 180:35-40.
40. Meguro H., Kervina M., Wright P.F. Antibody-dependent cell-mediated cytotoxicity against cells infected with respiratory syncytial virus: characterization of in vitro and in vivo properties. J Immunol 1979, 122:2521-2526.
41. Rudraraju R., Surman S., Jones B., Sealy R., Woodland D.L., Hurwitz J.L. Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut. Virology 2011, 410:429-436.
42. Dave V.P., Allan J.E., Slobod K.S., Smith S.F., Ryan K., Powell U., et al. Viral cross-reactivity and antigenic determinants recognized by human parainfluenza virus type 1-specific cytotoxic T-cells. Virology 1994, 199:376-383.
43. Rudraraju R., Surman S.L., Jones B.G., Sealy R., Woodland D.L., Hurwitz J.L. Reduced frequencies and heightened CD103 expression among virus-induced CD8(+) T cells in the respiratory tract airways of vitamin A-deficient mice. Clin Vaccine Immunol 2012, 19:757-765.
44. Smith F.S., Portner A., Leggiadro R.J., Turner E.V., Hurwitz J.L. Age-related development of human memory T-helper and B-cell responses toward parainfluenza virus type-1. Virology 1994, 205:453-461.
45. Koff W.C., Caplan F.R., Case S., Halstead S.B. Cell-mediated immune response to respiratory syncytial virus infection in owl monkeys. Clin Exp Immunol 1983, 53:272-280.
46. Sato H., Albrecht P., Reynolds D.W., Stagno S., Ennis F.A. Transfer of measles, mumps, and rubella antibodies from mother to infant. Its effect on measles, mumps, and rubella immunization. Am J Dis Child 1979, 133:1240-1243.
47. Kim D., Huey D., Oglesbee M., Niewiesk S. Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies. Blood 2011, 117:6143-6151.
48. Van de Perre P. Transfer of antibody via mother's milk. Vaccine 2003, 21:3374-3376.
49. Prince G.A., Horswood R.L., Chanock R.M. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 1985, 55:517-520.
50. De Vincenzo J.P., Leombruno D., Soiffer R.J., Siber G.R. Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation. Bone Marrow Transplant 1996, 17:1051-1056.
51. Malley R., DeVincenzo J., Ramilo O., Dennehy P.H., Meissner H.C., Gruber W.C., et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998, 178:1555-1561.
52. Niewiesk S. Studying experimental measles virus vaccines in the presence of maternal antibodies in the cotton rat model (Sigmodon hispidus). Vaccine 2001, 19:2250-2253.
53. Blomqvist G.A., Lovgren-Bengtsson K., Morein B. Influence of maternal immunity on antibody and T-cell response in mice. Vaccine 2003, 21:2022-2031.
54. Sami I.R., Piazza F.M., Johnson S.A., Darnell M.E., Ottolini M.G., Hemming V.G., et al. Systemic immunoprophylaxis of nasal respiratory syncytial virus infection in cotton rats. J Infect Dis 1995, 171:440-443.
55. Johnson S., Oliver C., Prince G.A., Hemming V.G., Pfarr D.S., Wang S.C., et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997, 176:1215-1224.
56. Bousse T., Chambers R.L., Scroggs R.A., Portner A., Takimoto T. Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment. Virus Res 2006, 121:23-32.
57. Sealy R., Jones B.G., Surman S.L., Hurwtiz J.L. Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1. Vaccine 2010, 28:6749-6756.
58. Crotty S., Felgner P., Davies H., Glidewell J., Villarreal L., Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003, 171:4969-4973.